{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:08:37Z","timestamp":1738645717876,"version":"3.35.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.leukres.2025.107641","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:14:08Z","timestamp":1736036048000},"page":"107641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The presence of clonal isotype switch after autologous stem cell transplantation as a prognostic biomarker for long-term survival in patients with multiple myeloma"],"prefix":"10.1016","volume":"149","author":[{"given":"Hanwool","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngrok","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misuk","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeongsic","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2025.107641_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061285","article-title":"Multiple myeloma: heterogeneous in every way","volume":"13","author":"Schavgoulidze","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.leukres.2025.107641_bib2","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2025.107641_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/hon.936","article-title":"Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance?","volume":"28","author":"Sucak","year":"2010","journal-title":"Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.leukres.2025.107641_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.leukres.2025.107641_bib5","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2017005447","article-title":"Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT","volume":"1","author":"Ho","year":"2017","journal-title":"Blood Adv."},{"issue":"26","key":"10.1016\/j.leukres.2025.107641_bib8","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107641_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/hematology.2022000347","article-title":"High or low? Assessing disease risk in multiple myeloma","volume":"2022","author":"Schmidt","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"9","key":"10.1016\/j.leukres.2025.107641_bib10","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","article-title":"Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma","volume":"110","author":"Gonz\u00e1lez","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.107641_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3324\/haematol.2010.030882","article-title":"Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents","volume":"96","author":"Fern\u00e1ndez de Larrea","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2025.107641_bib12","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/j.clml.2018.12.022","article-title":"Immune signatures associated with clonal isotype switch after autologous stem cell transplantation for multiple myeloma","volume":"19","author":"Ye","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.leukres.2025.107641_bib13","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2013.084350","article-title":"Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution","volume":"98","author":"Tovar","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2025.107641_bib14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.2008.07374.x","article-title":"Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma","volume":"143","author":"Mark","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"17-18","key":"10.1016\/j.leukres.2025.107641_bib15","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.clinbiochem.2011.05.022","article-title":"Evaluation of two automated capillary electrophoresis systems for human serum protein analysis","volume":"44","author":"Chartier","year":"2011","journal-title":"Clin. Biochem"},{"issue":"1","key":"10.1016\/j.leukres.2025.107641_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalh\u00e3es","year":"2013","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.leukres.2025.107641_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194867","article-title":"Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity","volume":"13","author":"Suzuki","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.leukres.2025.107641_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2025.107641_bib19","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1182\/blood.V91.9.3518","article-title":"Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation","volume":"91","author":"Zent","year":"1998","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2025.107641_bib20","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2025.107641_bib21","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2025.107641_bib22","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","volume":"14","author":"Coffey","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:09:14Z","timestamp":1738573754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":20,"alternative-id":["S0145212625000013"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107641","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The presence of clonal isotype switch after autologous stem cell transplantation as a prognostic biomarker for long-term survival in patients with multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107641"}}